Table 3.
Adaption of the American College of Clinical Oncology Guidelines 2017
| Cancer | Line of treatment | EGFR/ALK/ROS gene mutations | TPS | Agent |
|---|---|---|---|---|
| Stage 4 NSCLC – squamous cell | First | Negative | >50% | Single agent pembrolizumab |
| Stage 4 NSCLC – nonsquamous cell | First | Negative | >50% | Single agent pembrolizumab |
| Stage 4 NSCLC | Second (received first-line chemotherapy) | Negative | >1% | Single-agent nivolumab, pembrolizumab or atezolizumab |
| Stage 4 NSCLC | Second (received first-line chemotherapy) | Negative | <1% or unknown | Single-agent nivolumab or atezolizumab |
Notes: Data from Hanna et al.36
Abbreviations: EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS, reactive oxygen species; TPS, tumor proportion score; NSCLC, non-small cell lung cancer.